Research Paper Volume 13, Issue 1 pp 351—363
ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration
Figure 5. Correlations between the CNV of ADRB1, immune cell infiltration, and prognosis. (A) High amplification of ADRB1 in B cells and dendritic cells (p<0.001); (B) High levels of B cells and ADRB1 suggested better prognosis of BRCA (p<0.05). CNV, copy number variations; BRCA, breast cancer.